The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Deoxycorticosterone acetate 56 47 3 RCSB PDB 3A66: Crystal structure of 6 aminohexanoate dimer hydrolase S112A G181D H266N D370Y mutant with substrate Dehydroacetic Acid Dihexa c Met HGFR TargetMol